NCT05164120View on ClinicalTrials.gov

Safety, Tolerability, and Treatment Effect of Belnacasan in Patients With COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 14, 2021

Primary Completion Date

July 18, 2022

Study Completion Date

October 11, 2022

Conditions
COVID-19
Interventions
DRUG

Belnacasan

Oral administration

DRUG

Placebo

Tablet containing 0mg of API

Trial Locations (2)

20010

MedStar Washington Hospital Center, Washington D.C.

21237

MedStar Franklin Square, Baltimore

Sponsors

Lead Sponsor

MedStar Health
All Listed Sponsors
lead

MedStar Health

OTHER

NCT05164120 - Safety, Tolerability, and Treatment Effect of Belnacasan in Patients With COVID-19 | Biotech Hunter | Biotech Hunter